Listed

Indaptus Therapeutics, Inc.

INDPNasdaqCIK 1857044HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$1.8m, Q2 FY2026
Net income−$1.8m, Q2 FY2026
Indaptus Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$k2,227Research and development, Q3 FY2023, three months to 2023-09-30$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figure2,035Research and development, Q4 FY2023, three months to 2023-12-31$2.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-13, accession 0001493152-25-010136. Derived: 12-month figure less the 9-month figure.Report this figure1,591Research and development, Q1 FY2024, three months to 2024-03-31$1.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-14, accession 0001641172-25-010099.Report this figure1,714Research and development, Q2 FY2024, three months to 2024-06-30$1.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-13, accession 0001641172-25-023333.Report this figure1,466Research and development, Q3 FY2024, three months to 2024-09-30$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure2,480Research and development, Q4 FY2024, three months to 2024-12-31$2.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-17, accession 0001493152-26-010585. Derived: 12-month figure less the 9-month figure.Report this figure2,811Research and development, Q1 FY2025, three months to 2025-03-31$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure2,167Research and development, Q2 FY2025, three months to 2025-06-30$2.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure1,518Research and development, Q3 FY2025, three months to 2025-09-30$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure2,845Research and development, Q4 FY2025, three months to 2025-12-31$2.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-17, accession 0001493152-26-010585. Derived: 12-month figure less the 9-month figure.Report this figure491Research and development, Q1 FY2026, three months to 2026-03-31$491.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure363Research and development, Q2 FY2026, three months to 2026-06-30$363.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure
Operating income$k(4,248)Operating income, Q3 FY2023, three months to 2023-09-30−$4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figure(4,180)Operating income, Q4 FY2023, three months to 2023-12-31−$4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-13, accession 0001493152-25-010136. Derived: 12-month figure less the 9-month figure.Report this figure(3,943)Operating income, Q1 FY2024, three months to 2024-03-31−$3.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-14, accession 0001641172-25-010099.Report this figure(4,109)Operating income, Q2 FY2024, three months to 2024-06-30−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-13, accession 0001641172-25-023333.Report this figure(3,142)Operating income, Q3 FY2024, three months to 2024-09-30−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure(4,172)Operating income, Q4 FY2024, three months to 2024-12-31−$4.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-17, accession 0001493152-26-010585. Derived: 12-month figure less the 9-month figure.Report this figure(4,573)Operating income, Q1 FY2025, three months to 2025-03-31−$4.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure(4,457)Operating income, Q2 FY2025, three months to 2025-06-30−$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure(2,648)Operating income, Q3 FY2025, three months to 2025-09-30−$2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure(8,156)Operating income, Q4 FY2025, three months to 2025-12-31−$8.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-17, accession 0001493152-26-010585. Derived: 12-month figure less the 9-month figure.Report this figure(2,160)Operating income, Q1 FY2026, three months to 2026-03-31−$2.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure(1,809)Operating income, Q2 FY2026, three months to 2026-06-30−$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure
Income tax$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(3,922)Net income, Q3 FY2023, three months to 2023-09-30−$3.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figure(4,003)Net income, Q4 FY2023, three months to 2023-12-31−$4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-13, accession 0001493152-25-010136. Derived: 12-month figure less the 9-month figure.Report this figure(3,807)Net income, Q1 FY2024, three months to 2024-03-31−$3.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure(4,015)Net income, Q2 FY2024, three months to 2024-06-30−$4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure(3,069)Net income, Q3 FY2024, three months to 2024-09-30−$3.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure(4,131)Net income, Q4 FY2024, three months to 2024-12-31−$4.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-17, accession 0001493152-26-010585. Derived: 12-month figure less the 9-month figure.Report this figure(4,532)Net income, Q1 FY2025, three months to 2025-03-31−$4.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure(5,229)Net income, Q2 FY2025, three months to 2025-06-30−$5.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure(2,975)Net income, Q3 FY2025, three months to 2025-09-30−$3.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure(8,112)Net income, Q4 FY2025, three months to 2025-12-31−$8.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-17, accession 0001493152-26-010585. Derived: 12-month figure less the 9-month figure.Report this figure(2,541)Net income, Q1 FY2026, three months to 2026-03-31−$2.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure(1,795)Net income, Q2 FY2026, three months to 2026-06-30−$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure
Diluted EPS$ per share(0.47)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figurenot reported(0.45)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-14, accession 0001641172-25-010099.Report this figure(13.16)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$13.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-13, accession 0001641172-25-023333.Report this figure(9.04)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$9.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figurenot reported(9.11)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$9.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure(9.09)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$9.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure(2.98)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$2.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figurenot reported(0.23)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure(0.02)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure
Basic EPS$ per share(0.47)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.47 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figurenot reported(0.45)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-14, accession 0001641172-25-010099.Report this figure(13.16)Basic EPS, Q2 FY2024, three months to 2024-06-30−$13.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-13, accession 0001641172-25-023333.Report this figure(9.04)Basic EPS, Q3 FY2024, three months to 2024-09-30−$9.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figurenot reported(9.11)Basic EPS, Q1 FY2025, three months to 2025-03-31−$9.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure(9.09)Basic EPS, Q2 FY2025, three months to 2025-06-30−$9.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure(2.98)Basic EPS, Q3 FY2025, three months to 2025-09-30−$2.98 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figurenot reported(0.23)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure(0.02)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure

Balance sheet

Cash and equivalents$7.6m, Q2 FY2026
Shareholders' equity$11.4m, Q2 FY2026
Indaptus Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m16.0Cash and equivalents, Q3 FY2023, at 2023-09-30$16.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-06, accession 0001493152-23-039523.Report this figure13.4Cash and equivalents, FY2023, at 2023-12-31$13.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-13, accession 0001493152-25-010136.Report this figure9.7Cash and equivalents, Q1 FY2024, at 2024-03-31$9.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-08, accession 0001493152-24-018162.Report this figure7.3Cash and equivalents, Q2 FY2024, at 2024-06-30$7.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-12, accession 0001493152-24-031158.Report this figure7.4Cash and equivalents, Q3 FY2024, at 2024-09-30$7.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figure5.8Cash and equivalents, FY2024, at 2024-12-31$5.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-17, accession 0001493152-26-010585.Report this figure3.9Cash and equivalents, Q1 FY2025, at 2025-03-31$3.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-14, accession 0001641172-25-010099.Report this figure6.2Cash and equivalents, Q2 FY2025, at 2025-06-30$6.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-13, accession 0001641172-25-023333.Report this figure5.8Cash and equivalents, Q3 FY2025, at 2025-09-30$5.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure8.5Cash and equivalents, FY2025, at 2025-12-31$8.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure1.5Cash and equivalents, Q1 FY2026, at 2026-03-31$1.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure7.6Cash and equivalents, Q2 FY2026, at 2026-06-30$7.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure
Current assets$m16.8Current assets, Q3 FY2023, at 2023-09-30$16.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-06, accession 0001493152-23-039523.Report this figure14.0Current assets, FY2023, at 2023-12-31$14.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-13, accession 0001493152-25-010136.Report this figure10.3Current assets, Q1 FY2024, at 2024-03-31$10.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0001493152-24-018162.Report this figure7.5Current assets, Q2 FY2024, at 2024-06-30$7.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-12, accession 0001493152-24-031158.Report this figure7.6Current assets, Q3 FY2024, at 2024-09-30$7.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figure6.6Current assets, FY2024, at 2024-12-31$6.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-17, accession 0001493152-26-010585.Report this figure5.0Current assets, Q1 FY2025, at 2025-03-31$5.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-14, accession 0001641172-25-010099.Report this figure6.4Current assets, Q2 FY2025, at 2025-06-30$6.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-13, accession 0001641172-25-023333.Report this figure6.4Current assets, Q3 FY2025, at 2025-09-30$6.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure9.3Current assets, FY2025, at 2025-12-31$9.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure2.2Current assets, Q1 FY2026, at 2026-03-31$2.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figurenot reported
Total assets$m17.8Total assets, Q3 FY2023, at 2023-09-30$17.8m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-06, accession 0001493152-23-039523.Report this figure14.9Total assets, FY2023, at 2023-12-31$14.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-13, accession 0001493152-25-010136.Report this figure10.9Total assets, Q1 FY2024, at 2024-03-31$10.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0001493152-24-018162.Report this figure8.1Total assets, Q2 FY2024, at 2024-06-30$8.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-12, accession 0001493152-24-031158.Report this figure8.2Total assets, Q3 FY2024, at 2024-09-30$8.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figure7.3Total assets, FY2024, at 2024-12-31$7.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-17, accession 0001493152-26-010585.Report this figure5.4Total assets, Q1 FY2025, at 2025-03-31$5.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-14, accession 0001641172-25-010099.Report this figure6.8Total assets, Q2 FY2025, at 2025-06-30$6.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-13, accession 0001641172-25-023333.Report this figure6.8Total assets, Q3 FY2025, at 2025-09-30$6.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure9.3Total assets, FY2025, at 2025-12-31$9.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figurenot reported12.0Total assets, Q2 FY2026, at 2026-06-30$12.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure
Current liabilities$m2.4Current liabilities, Q3 FY2023, at 2023-09-30$2.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-06, accession 0001493152-23-039523.Report this figure2.8Current liabilities, FY2023, at 2023-12-31$2.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-13, accession 0001493152-25-010136.Report this figure1.5Current liabilities, Q1 FY2024, at 2024-03-31$1.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0001493152-24-018162.Report this figure1.9Current liabilities, Q2 FY2024, at 2024-06-30$1.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-12, accession 0001493152-24-031158.Report this figure2.2Current liabilities, Q3 FY2024, at 2024-09-30$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figure3.4Current liabilities, FY2024, at 2024-12-31$3.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-17, accession 0001493152-26-010585.Report this figure2.6Current liabilities, Q1 FY2025, at 2025-03-31$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-14, accession 0001641172-25-010099.Report this figure8.5Current liabilities, Q2 FY2025, at 2025-06-30$8.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-13, accession 0001641172-25-023333.Report this figure2.2Current liabilities, Q3 FY2025, at 2025-09-30$2.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure6.2Current liabilities, FY2025, at 2025-12-31$6.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure0.9Current liabilities, Q1 FY2026, at 2026-03-31$933.0k. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figurenot reported
Total liabilities$m2.5Total liabilities, Q3 FY2023, at 2023-09-30$2.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-06, accession 0001493152-23-039523.Report this figure2.8Total liabilities, FY2023, at 2023-12-31$2.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-13, accession 0001493152-25-010136.Report this figure1.6Total liabilities, Q1 FY2024, at 2024-03-31$1.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0001493152-24-018162.Report this figure2.0Total liabilities, Q2 FY2024, at 2024-06-30$2.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-12, accession 0001493152-24-031158.Report this figure2.2Total liabilities, Q3 FY2024, at 2024-09-30$2.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figure3.4Total liabilities, FY2024, at 2024-12-31$3.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-13, accession 0001493152-25-010136.Report this figurenot reportednot reportednot reported6.2Total liabilities, FY2025, at 2025-12-31$6.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figurenot reported0.6Total liabilities, Q2 FY2026, at 2026-06-30$615.4k. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure
Shareholders' equity$m15.3Shareholders' equity, Q3 FY2023, at 2023-09-30$15.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figure12.1Shareholders' equity, FY2023, at 2023-12-31$12.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-17, accession 0001493152-26-010585.Report this figure9.4Shareholders' equity, Q1 FY2024, at 2024-03-31$9.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure6.2Shareholders' equity, Q2 FY2024, at 2024-06-30$6.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure6.0Shareholders' equity, Q3 FY2024, at 2024-09-30$6.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure3.9Shareholders' equity, FY2024, at 2024-12-31$3.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure2.8Shareholders' equity, Q1 FY2025, at 2025-03-31$2.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure(1.7)Shareholders' equity, Q2 FY2025, at 2025-06-30−$1.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure4.6Shareholders' equity, Q3 FY2025, at 2025-09-30$4.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure3.2Shareholders' equity, FY2025, at 2025-12-31$3.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure1.2Shareholders' equity, Q1 FY2026, at 2026-03-31$1.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure11.4Shareholders' equity, Q2 FY2026, at 2026-06-30$11.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure

Cash flow

Operating cash flow−$1.9m, Q2 FY2026
Indaptus Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(3,734)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001493152-24-044537. Derived: 9-month figure less the 6-month figure.Report this figure(2,602)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-13, accession 0001493152-25-010136. Derived: 12-month figure less the 9-month figure.Report this figure(3,936)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$3.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-14, accession 0001641172-25-010099.Report this figure(2,478)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-13, accession 0001641172-25-023333. Derived: 6-month figure less the 3-month figure.Report this figure(2,513)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$2.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001493152-25-021759. Derived: 9-month figure less the 6-month figure.Report this figure(3,396)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001493152-26-010585. Derived: 12-month figure less the 9-month figure.Report this figure(5,047)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$5.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure(4,018)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037579. Derived: 6-month figure less the 3-month figure.Report this figure(2,567)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001493152-25-021759. Derived: 9-month figure less the 6-month figure.Report this figure(3,191)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$3.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-17, accession 0001493152-26-010585. Derived: 12-month figure less the 9-month figure.Report this figure(7,010)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$7.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure(1,928)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001493152-26-037579. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)116.13m, Q2 FY2026
Indaptus Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares8.3Diluted shares (weighted), Q3 FY2022, three months to 2022-09-308,258,597 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-06, accession 0001493152-23-039523.Report this figure8.4Diluted shares (weighted), Q1 FY2023, three months to 2023-03-318,401,047 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0001493152-24-018162.Report this figure8.4Diluted shares (weighted), Q2 FY2023, three months to 2023-06-308,401,047 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-12, accession 0001493152-24-031158.Report this figure8.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-308,401,047 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001493152-24-044537.Report this figure8.4Diluted shares (weighted), Q1 FY2024, three months to 2024-03-318,442,364 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-14, accession 0001641172-25-010099.Report this figure0.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30305,140 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-13, accession 0001641172-25-023333.Report this figure0.3Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30339,659 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure0.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31497,794 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure0.6Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30574,923 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure1.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30997,038 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001493152-25-021759.Report this figure11.0Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3110,956,650 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001493152-26-023362.Report this figure116Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30116,131,213 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure

Shares outstanding: 133.24mShares outstanding, period not labelled, at 2026-08-13133,242,324 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001493152-26-037579.Report this figure at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.